Recently,the Center for Drug Evaluation of the NMPA announced the acceptance of the investigational new drug (IND) application for Novartis's PIT565 injection.

Ionis has revealed that the FDA has accepted the New Drug Application for donidalorsen, intended for the preventive treatment of HAE.

Tiziana Life Sciences announced that its intranasally administered anti-CD3 monoclonal antibody, foralumab.

CinFina Pharma showcases encouraging Phase 1 study findings during a poster session for CIN-109 and a late-breaking poster for CIN-110.

Recently, Vivoryon Therapeutics presented new analysis data for varoglutamstat at the 2024 American Society of Nephrology (ASN) meeting.

Xencor has administered the initial dose to a participant in the Phase 1/2 trial of XmAb®942, aimed at treating inflammatory bowel disease.

Givosiran Sodium, a groundbreaking therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals.

HiFiBiO Therapeutics has gained FDA approval for its IND application concerning HFB200604, a leading BTLA agonist antibody.

Casdatifan is a small molecule drug designed to target HIF-2α, and it is being developed for the treatment of neoplasms, urogenital diseases, and digestive system disorders.

Sutro Biopharma has launched the REFRαME-P1 Trial to support registration of Luvelta for children with CBF/GLIS AML.

Novartis will acquire a clinical-stage molecular glue named MRT-6160, providing Monte Rosa with an upfront payment of $150 million.

UCB presented Phase 2a findings from the TOGETHER (AH0003) trial, which explored the safety, effectiveness, and tolerability of bepranemab.